AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Celltrion's asthma treatment Omlyclo, a biosimilar of Novartis's Xolair, has received Canadian approval for chronic urticaria, rhinosinusitis, and allergic asthma ...

A new study published in the Ear, Nose and Throat Journal found that the severity of chronic rhinosinusitis with nasal ...

Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

A research team led by Professor Lee Kun-hee at Gangdong Kyunghee University Hospital has announced new evaluation criteria ...

The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...

Do you find yourself sneezing, itching or battling watery eyes as the seasons change? If so, you may have a pollen ...

"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

The FDA has accepted for review the BLA for mepolizumab as an add-on maintenance treatment for eosinophilic COPD.

Whether you want passive income or not, dividend-paying stocks tend to outperform their non-dividend-paying cousins.

Group 2 Innate lymphoid cells (ILC2) are a source of type 2 cytokines, such as interleukin-5 (IL-5). Here Troch, Jakob et al. show a non-redundant role of ILC2-derived IL-5 required for the ...